US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule
Executive Summary
Agency’s struggle to meet user fee commitments despite travel restrictions expected to worsen as pandemic continues into 2021.
You may also be interested in...
US FDA Looks To Resume Unannounced Inspections In India And China
After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”
US FDA Looks To Resume Unannounced Inspections In India And China
After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”
US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.